Intercept Pharmaceuticals: The $85 Trade That Crashed | Stock Sharks Case Study

This is a real case study on Intercept Pharmaceuticals ($ICPT) — and a brutal lesson in biotech trading.

We entered the stock at $85 before positive phase 2 trial results sent it soaring to $105… but greed cost us. When the FDA rejected phase 3 data, the stock collapsed, and we exited at $40.

Biotech stocks can make or break portfolios overnight — here’s what this trade taught us about volatility, timing, and taking profits when you can.

🔔 Subscribe for more trading stories and case studies from Stock Sharks.


The Sharks Disclaimer:

All videos and posts are for informational purposes only and should not be considered financial advice. Always do your own research before making any investment decisions.
--

The Sharks Program

Join Stock Sharks for exclusive, high-quality research designed for serious traders, investors, and financial professionals.

Our community is built for those who already know the game and want deeper insight, faster intel, and an edge. Register at the link in our bio.


#StockSharks #ICPT #InterceptPharmaceuticals #BiotechStocks #Investing #Trading #Finance #StockMarket #CaseStudy #FDA #ClinicalTrials #BiotechInvesting